Search

Author/Creator Bruno, Christopher J.

1. A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections. (October 2022)

Authors:
Sun, Yihong; Fan, Jia; Chen, Gang; Chen, Xiaofei; Du, Xiaoling; Wang, Ye; Wang, Hui; Sun, Fang; Johnson, Matthew G.; Bensaci, Mekki; Huntington, Jennifer A.; Bruno, Christopher J.
Journal:
International journal of infectious diseases
Issue:
Volume 123(2022)
Page Start:
157
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia. (22nd November 2022)

Authors:
Gao, Wei; Patel, Yogesh T.; Zhang, Zufei; Johnson, Matthew G.; Fiedler‐Kelly, Jill; Bruno, Christopher J.; Rhee, Elizabeth G.; Anda, Carisa De; Feng, Hwa‐Ping
Journal:
Journal of clinical pharmacology
Issue:
Volume 63:Number 3(2023)
Page Start:
352
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. (12th January 2022)

Authors:
Martin-Loeches, Ignacio; Timsit, Jean-François; Kollef, Marin H.; Wunderink, Richard G.; Shime, Nobuaki; Nováček, Martin; Kivistik, Ülo; Réa-Neto, Álvaro; Bruno, Christopher J.; Huntington, Jennifer A.; Lin, Gina; Jensen, Erin H.; Motyl, Mary; Yu, Brian; Gates, Davis; Butterton, Joan R.; Rhee, El...
Journal:
Journal of antimicrobial chemotherapy
Issue:
Volume 77:Number 4(2022)
Page Start:
1166
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia. (18th September 2020)

Authors:
Zhang, Zufei; Patel, Yogesh T.; Fiedler‐Kelly, Jill; Feng, Hwa‐Ping; Bruno, Christopher J.; Gao, Wei
Journal:
Journal of clinical pharmacology
Issue:
Volume 61:Number 2(2021)
Page Start:
254
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia and End‐Stage Renal Disease Receiving Intermittent Hemodialysis. (2nd October 2022)

Authors:
Feng, Hwa‐Ping; Patel, Yogesh T.; Zhang, Zufei; Fiedler‐Kelly, Jill; Bruno, Christopher J.; Rhee, Elizabeth G.; De Anda, Carisa; Gao, Wei
Journal:
Journal of clinical pharmacology
Issue:
Volume 63:Number 2(2023)
Page Start:
166
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial. Issue 4 (23rd January 2023)

Authors:
Roilides, Emmanuel; Ashouri, Negar; Bradley, John S.; Johnson, Matthew G.; Lonchar, Julia; Su, Feng-Hsiu; Huntington, Jennifer A.; Popejoy, Myra W.; Bensaci, Mekki; De Anda, Carisa; Rhee, Elizabeth G.; Bruno, Christopher J.
Journal:
Pediatric infectious disease journal
Issue:
Volume 42:Issue 4(2023)
Page Start:
292
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗